HAIFA, Israel, Jan. 25, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI) announced today that H.C. Wainwright & Co., LLC, the sole book-running manager of its previously announced bought offering of 12,244,898 shares of common stock and warrants to purchase up to 7,346,939 shares of its common stock, has exercised in full its over-allotment option (the "Over-Allotment Option") to purchase an additional 1,836,735 shares of common stock and warrants to purchase an additional 1,102,041 shares of common stock at the public offering price of US$1.225 per share and associated warrant. After taking into account the Over-Allotment Option being exercised in full, the aggregate gross proceeds to the Company (assuming no exercise of the warrants) in the bought offering were US$17.25 million, before deducting underwriting discounts and commissions and other offering expenses. The closing of the bought offering, including the Over-Allotment Option, occurred on January 25, 2017.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.  The securities described above were offered by the Company pursuant to a "shelf" registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC") on October 30, 2014. A final prospectus supplement and the accompanying prospectus related to the offering was filed with the SEC on January 20, 2017, copies of which can be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, New York, NY 10022, by calling 646-975-6996 or by email at placements@hcwco.com or at the SEC's website at http://www.sec.gov.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company has reported robust clinical trial data in multiple indications for its patented PLX (PLacental eXpanded) cells. The cell products release a range of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cell products are grown using the Company's proprietary three-dimensional expansion technology. They are off-the-shelf, requiring no tissue matching prior to administration.

Pluristem has a strong intellectual property position; Company-owned and operated, GMP-certified manufacturing and research facilities; strategic relationships with major research institutions; and a seasoned management team.

Contact:Pluristem Therapeutics Inc.Karine Kleinhaus, MD, MPHDivisional VP, North America1-914-512-4109karinek@pluristem.com

Primary Logo